Vebreltinib
Small molecule
Also known as APL-101, PLB-1001, CBI-3103, CBT-101
Evidence outlook
Approved: MET exon 14 skipping non-small cell lung cancer (conditional approval) (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Weak signal
Also in development:Non-Small Cell Lung Cancer with MET Exon 14 Skipping · Phase 3 · investigational in the US
Also approved (3)
- MET exon 14 skipping non-small cell lung cancer (conditional approval)
- MET-amplified non-small cell lung cancer
- PTPRZ1-MET fusion high-grade glioma
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
KUNPENG-3 NCT06930794 · Non-Small Cell Lung Cancer Registry: NCT06930794 | 3 | Introductory phase-Dose-limiting toxicity (DLT) Incidence of DLT events during the observation period (1 year); Incidence and severity of adverse events (AEs) . (1 year); Introductory phase-Recommended dosage for MTD and/or co-administration. (1 year); Randomized control period-Progression-free survival (PFS) as assessed by the Blinded Independent Center Review Board (BICR) according to RECIST V1.1 in the MET GCN ≥6-enriched population. (4 years); Randomized control period-Progression-free survival (PFS) as assessed by BICR according to the criteria for evaluating the efficacy of solid tumors (RECIST V1.1) in the full MET GCN ≥4 population. (4 years) 2029-02 | In progress: results expected 1 Feb 2029 | not yet graded | link ↗ |
View 3 more trials
KYLIN-3 NCT06970782 · Non-Small-Cell Lung Cancer Registry: NCT06970782 | 3 | Progression-Free Survival (PFS) by BICR (2 years) 2027-12-31 | In progress: results expected 31 Dec 2027 | not yet graded | link ↗ |
NCT05989542 NCT05989542 · Non-small Cell Lung Cancer Registry: NCT05989542 | 3 | Confirmed Objective Response Rate Evaluated by IRC (2 years) 2026-09-30 | In progress: primary completion was expected 30 Sept 2026; results not posted | not yet graded | link ↗ |
KUNPENG NCT04258033 · Non-small Cell Lung Cancer This is an open-label, single-arm study with no randomization and no comparator group. The response rate in cohort 1 was high and its confidence interval cleared a preset benchmark, but without a control group the size of the drug's effect cannot be judged directly. Registry: NCT04258033 | 2 | Objective response rate (2 years) 2024-05-14 | Primary endpoint objective response rate 75% (95% CI, 61.1 to 86) per blinded independent review committee | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other MET drugs
Capmatinib, Telisotuzumab Vedotin, Tepotinib, ASKC202, Glumetinib and 7 more. Compare all 13 MET drugs
This mechanism is crowded: 12 other tracked programmes target it, 3 of them ahead of this one.
This drug's own stage for Glioma: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Vebreltinib: this drug | Phase 1 | Small molecule | MET | not yet graded | No reviewed efficacy summary in this indication | |
| Dabrafenib | Approved | Small molecule | BRAF V600E/V600K/V600D (also wild-type BRAF/CRAF) | not yet graded | No reviewed efficacy summary in this indication | |
| Dordaviprone | Approved | Small molecule | Mitochondrial caseinolytic protease P (ClpP), Dopamine D2 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Temozolomide | Approved | Small molecule | DNA alkylation (O6-guanine) | Partial signal | NCT00626990: Overall survival: adjuvant temozolomide vs none, median 82.3 vs 46.9 months, hazard ratio 0.64 (95% CI 0.52 to 0.79), p<0.0001; concurrent temozolomide vs none, 66.9 vs 60.4 months, hazard ratio 0.97 (95% CI 0.73 to 1.28), p=0.76 (CT.gov posted results). | |
| Tovorafenib | Approved | Small molecule | Kinase Inhibitor | Weak signal | No reviewed efficacy summary in this indication | |
| Trametinib | Approved | Small molecule | MEK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Luvometinib | Phase 3 | Small molecule | MEK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Safusidenib | Phase 3 | Small molecule | Mutant IDH1 | not yet graded | No reviewed efficacy summary in this indication | |
| Abemaciclib (Verzenio) | Phase 2 | Small molecule | CDK4 and CDK6 | not yet graded | No reviewed efficacy summary in this indication | |
| Olutasidenib | Phase 2 | Small molecule | Mutant IDH1 | not yet graded | No reviewed efficacy summary in this indication | |
| Crelosidenib | Phase 1 | Small molecule | Mutant IDH1 and IDH2 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
6 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Vebreltinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.